Placeholder

Advair: the drug to watch

$30.00

Copyright: This PDF purchase is for a Single user for review or filing purposes only. The PDF is watermarked. If you are interested in a PDF reprint to post on your website or distribute electronically, or hard-copy reprints, please contact Marah Walsh at mwalsh@pharmavoice.com.

SKU: 1630. Categories: , .

Product Description

Advair is the drug to watch
The inhaler is well on its way to blockbuster status in the U.S., where it debuted in April 2001. Advair Diskus already is the fastest-growing asthma medicine in Europe, where it is marketed under the name Seretide, and Goldman Sachs analysts forecast that global sales of the drug will reach $2.4 billion by 2005.
Advair, which combines Flovent (fluticasone propinate) and Serevent (salmeterol xinafoate), is probably the biggest product launch GlaxoSmithKline will have, not only this year but for the next several years. The speed of its adoption by patients and physicians, according to analysts, makes Advair the most successfully launched asthma treatment in the past decade. After only four months on the U.S. market, Advair accounted for about 10% of all weekly prescriptions for respiratory controller medications. GlaxoSmithKline already is No. 1 in this market, claiming more than 30% of total U.S. sales thanks to the prominence of the company‚Äôs existing asthma products, Flovent and Serevent. And analysts are predicting that Advair will enable the company to expand its market share in the hotly contested…

Sidebars:
Selected Asthma Medications on the Market
The managed-care advantage

Experts on this topic
James Donohue, M.D. Professor of Medicine, Division of Pulmonary Medicine, The University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, N.C.; the School of Medicine of The University of North Carolina at Chapel Hill educates students and professionals of the health and biomedical sciences, conducts scholarly investigation in biomedical, behavioral, and social sciences, and renders service to the people and institutions of the state, region, nation, and, as appropriate, throughout the world
Simon Jose. VP, Respiratory Marketing, GlaxoSmithKline, Philadelphia; GlaxoSmithKline is a leading research-based pharmaceutical and healthcare company
Stuart Stoloff, M.D. Associate Professor of Family and Community Medicine, University of Nevada, Las Vegas; The Department of Family and Community Medicine is committed to excellence in graduate training in family medicine

FEEDBACK